Allergy-Immunology
Cardiology
Endocrinology
Gastroenterology
General Internal Medicine
Geriatric Medicine
Hematology / Oncology
Hepatology
Hospital Medicine
Immunotherapy
Infectious Diseases
Nephrology / Hypertension
Pulmonary & Critical Care
Rheumatology
Sports Medicine

Bibliography 1999

2004 | 2003 | 2002 | 2001 | 2000 | 1999

  1. Argiris A, Mathur U, Wilets I, Mildvan D. Abnormalities of serum amylase and lipase in HIV positive patients. Am J of Gastroenterology. 94:1248-52, 1999.

  2. Argiris A, Maun N, Berliner N. Mycobacterium avium intracellulare inclusions mimicking Gaucher cells. NEJM, 340:1372, 1999.

  3. Bennett CL, Bishop MR, Tallman MS, Somerfield MR, Feinglass J, Smith TJ. The association between physician reimbursement in the United States and use of hematopoietic colony stimulating factors as adjunct therapy for older patients with acute myeloid leukemia: Results from the 1997 American society of Clinical Oncology survey. Annals of Oncology, 10:1355-1359, 1999.

  4. Bennett CL, Stinson TJ, Yang T, Lurain JR The effect of reimbursement policies on the management of medicare patients with refractory ovarian cancer. Seminars in Oncology, 26(1):S40-45; 1999.

  5. Bennett CL, Lane D, Stinson T, Glatzel. M, Buntzel J. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Invest 1999 (in press).

  6. Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, Ernstoff MS, Ross SD. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer and Prostatic Diseases, 2: 4-8, 1999.

  7. Bennett CL, Pajeau TJ, Tallman MS, Stadtmauer EA, Marsh RW, Friedenberg W, Lazarus HM, Kaminer LS, Golub RM, Rowe JM. Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: An Eastern Cooperative Oncology Group (E1490) Trial. Annals of Oncology, 10:1-6, 1999.

  8. Bennett CL, Stinson TJ. Comparing cost-effectiveness analyses for the clinical oncology setting: the example of the GOG 111 trial. Cancer Invest, 108: 263-270, 1999.

  9. Bennett CL, Stinson TJ, Lane D, Amylon M, Land V, Laver J. A cost-analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoma: a case for prospective economic analysis in cooperative group trials. Med. Pediatr Oncol, 34:92-96, 1999.

  10. Bennett CL, Waters TM, Stinson TJ, Almagor O, Pavletic ZS, Tarantolo SR, Bishop MR. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant, 24: 555-560, 1999.

  11. Bennett CL, Weeks J., Somerfield M., Feinglass J., Smith T. Use of hematopoietic colony stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys to ASCO Clinical Practice Guidelines. J Clin Onc, 17: 3676-3681, 1999.

  12. Bach PD, Calhoun EA, Bennett CL. Prescription tracking as a sampling method for survey research: report from a mail survey of physicians about HIV card. Journal of Clin Epidemiology, 52: 147-150, 1999.

  13. Bach PB, Calhoun EA, Bennett CL. The relation between physician experience and patterns of care for patients with AIDS-related pneumocystis carinii pneumonia: results from a survey of 1,500 physicians in the United States. Chest, 115: 1563- 1569, 1999.

  14. Calhoun EA, Bennett CL, Peeples PA, Lurain JR, Roland PY, Weinstein JM, Fishman DA. Perceptions of cisplatin-related toxicity among ovarian cancer patients and gynecologic oncologists. Gynecol Oncol. 71:369-375, 1999.

  15. Dale W, Sartor O, Davis T, Bennett CL. Understanding barriers to the early detection of prostate cancer among lower socioeconomic men. Prostate Journal, 1999 (in press).

  16. Ferreira MR, Bennett RL, Gilman S, Mathewson S, Bennett CL. The diffusion of laparoscopic cholecystectomy in the Veterans Affairs Health Care System:1991-1995, Effective Clinical Practice, 2: 49-55, 1999.

  17. Freeman MB, Vose JM, Bennett CL, Anderson JR, Kessinger A, Turner K, Pierson J, Bishop M, Bierman P, Armitage JO. Costs of care for high-dose therapy and autologous transplantation for non-hodgkin’s lymphoma: Results from the University of Nebraska Medical Center 1989 through 1995. Bone Marrow Transplant, 24: 679-684, 1999.

  18. Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. J Am Med Assoc, 282:1453-1457, 1999.

  19. Kim SP, Knight S, Bennett CL. Low literacy and prostate cancer. Cancer Investigation, 1999 (in press).

  20. Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, Goldman JM, Guilhot F, Kantarjian HM, Lichtin AE, Talpaz M, Tura S. Review: an evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood, 94: 1517-1536, 1999.

  21. Benson III AB and Stucky-Marshall L. Treating primary liver cancer. Coping with Cancer 13(6):74-75, 1999.

  22. Benson III AB. NCCN practice guidelines for hepatobiliary cancers. Oncology 13:265-292, 1999.

  23. Desch CE, Benson III AB, Smith TJ, Flynn PJ, Krause C, Loprinzi CL, Minsky BD, Petrelli NJ, Pfister DG, Somerfield MR. Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. J Clin Oncol 17(4):1312-1321, 1999.

  24. Ettinger DS, Ajani J, Benson A, Clark OH, Engstrom P, Kandeel F, Kessinger A, Martin E, Nemcek A, O’Dorisio TM, Saltz L, Shibata S. NCCN practice guidelines for neuroendocrine tumors. Oncology 13:297-343, 1999.

  25. Hochster H, Ibrahim J, O'Dwyer PJ, Liebes L, Benson III AB, A phase II study of topotecan in advanced colorectal cancer: An Eastern Cooperative Oncology Group study (E4293). Cancer Therapeutics 2:37-43, 1999.

  26. Hudes GR, Lipsitz S, Grem J, Morrisey M, Weiner L, Kugler JW, Benson III AB. phase II study of 5-fluorouracil, leucovorin and a-interferon in metastatic or recurrent gastric carcinoma: An Eastern Cooperative Oncology Group Study (E5292). Cancer 85:290-294, 1999.

  27. Minsky BD, Neuberg D, Kelsen DP, Pisansky TM, Ginsberg RJ, Pajak T, Salter M, Benson III AB. Final report of intergroup trial 0122 (ECOG PE-289, RTOG 90-12): phase II neoadjuvant chemotherapy plus concurrent chemotherapy and high dose radiation for squamous cell carcinoma of the esophagus. Int’l J of Radiation Oncology, Biology, Physics, 43(3):517-523, 1999.

  28. Steele G, Herndon J, Bleday R, Russell A, Benson A, Hussain M, Burgess A, Tepper J, Mayer R. Sphincter sparing treatment for distal rectal adenocarcinoma. Ann Surg Oncol 6: 433-441, 1999.

  29. Bergan RC, Reed E, Myers CE, Headlee D, Brawley O, Cho HK, Figg WD, Tompkins A, Linehan WM, Kohler D, Steinberg SM and Blagosklonny M. A phase II study of high dose tamoxifen in patients with hormone refractory prostate cancer. Clinical Cancer Research, 5(9):2366-73, 1999.

  30. Blagosklonny MV, Chuman Y, Bergan RC and Fojo T. Mitogen activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells. Leukemia, 13:1028-1036, 1999.

  31. Figg WD, Raje S, Bauer KS, Tompkins A, Venzon D, Bergan RC, Chen A, Hamilton M, Pluda J, Reed E. Pharmacokinetics of thalidomide in an elderly prostate cancer population, Journal of Pharmaceutical Sciences, 88(1):121-5, 1999.

  32. Dierov J, Prosniak M, Gallia G, Gartenhaus RB. Increased G1 cyclin/cdk activity in cells overexpressing the candidate oncogene, MCT-1. Journal of Cellular Biochemistry, 74: 544-550, 1999.

  33. Dierov J. Sawaya BE, Prosniak M, Gartenhaus RB. Retinoic acid modulates a bimodal effect on cell cycle progression in human adult T-cell leukemia cells. Clinical Cancer Research. 5: 2540-2547, 1999.

  34. Stack MS, Gately S, Bafetti L, Enghild JJ, Soff GA. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochemical Journal, 340: 77-84, 1999.

  35. Twardowski P, Gately S, Gradishar W. Surrogate endpoints as a measure of efficacy in clinical trials of angiogenesis inhibitors. in: therapeutic implications of angiogenesis inhibitors and stimulators: current status and future directions, Landes Bioscience, Texas, 1999.

  36. Gordon LI, Kwaan HC. Thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the cancer patient. Seminars in Thrombosis and Hemostasis 25(2): 217-221, 1999.

  37. Gordon LI, Young M, Weller E, Habermann TM, Winter JN, Glick J, Ghosh C, Flynn P, Cassileth PA. A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated diffuse aggressive lymphomas: analysis of response, toxicity and dose intensity. Blood 94(10):3307-3314, 1999.

  38. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon LI, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Onc, 17:268-276, 1999.

  39. Douglas VK, Gordon LI, Goolsby CL, White CA, Peterson LC. Lymphoid aggregates in bone marrow mimic residual lymphoma following Rituximab therapy for non-Hodgkin’s lymphoma. Amer J Clin Pathol 112(6):844-853, 1999.

  40. Wiernik PH, Gordon, LI, Oken MM, Harris JE, O’Connell MJ. Evaluation of mitoguazone in patients with refractory chronic lymphocytic leukemia: a phase II study (P-H482) of the Eastern Cooperative Oncology Group. Leukemia & Lymphoma 35(3-4):375-377, 1999.

  41. Wiseman GA, White CA, Witzig TE, Gordon LI, Emmanouilides C, Raubitsched A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman Daniel SH, Grillo-Lopez, AJ. Radioimmunotherapy of relapsed non-hodgkin’s lymphoma with Zevalin a 90Y-labeled anti CD20 monoclonal antibody. Clin Cancer Research 5:3281s-3286s, (Suppl) 1999.

  42. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DHS, Parker E, Grillo-Lopez AJ. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+)B-cell non-hodgkin’s lymphoma. J Clin Oncol 17(12):3793-3803, 1999.

  43. Gradishar WJ, Recently initiated studies:neoadjuvant treatments in the next century. Semin. Oncol, 26:26-29, 1999.

  44. Gradishar WJ. Formulating guidelines for chemotherapy in advanced breast cancer. Oncology 13:231-235, 1999.

  45. Gradishar WJ. High-dose chemotherapy and breast cancer. JAMA, 282:1378-1380, 1999.

  46. Gradishar, WJ, Jordan VC, Hormonal therapy for breast cancer. Hematology/Oncology Clin North Am, 13:435-455, 1999.

  47. Carlson RW, Goldstein LJ, Gradishar WJ, et al. Update: national cancer care network practice guidelines for the treatment breast cancer guidelines. Oncology, 13:41-66, 1999.

  48. Breast Cancer Risk Reduction Guidelines Panel Members (Carlson R, Baraket R, Bevers T, Daly MB, Edge S, Garber JE, Gradishar W, Mahoney M, Sellin RV, Shapiro C, Singletary E, Theriault R, Ward J, Whittemore A, Williams C, Winer E. NCCN breast cancer risk-reduction guidelines. Oncology 13:241-254, 1999.

  49. Hensley ML, Schuchter LM, Lindley C, Meropol N, Cohen G, Broder G, Gradishar WJ et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 17:3333-3355, 1999.

  50. Noe LL, Becker RV, Gradishar WJ, Gore M, Trotter JP. The cost effectiveness of tamoxifen in the prevention of breast cancer. J Clin Onc, (suppl):S389-S406, 1999

  51. Sparano JA, Speyer J, Gradishar WJ et al. Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer. J Clin Oncol, 17:880-886, 1999.

  52. Green D, Blanc J, Foiles N. Spontaneous inhibitors of FVIII: kinetics of inactivation of human and porcine FVIII. J Lab Clin Med, 133:260-4. 1999.

  53. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA. Extended anticoagulation compared to placebo after three months of therapy for a first episode of idiopathic venous thromboembolism. N Engl J of Med, 340:921-927, 1999.

  54. Lorand L, Velasco PT, Lefebvre P, Green D. Autoimmune antibody in a hemorrhagic patient interacts with thrombicin-activated factor XIII in a unique manner. Blood, 93:909-917, 1999.

  55. Westerman MP, Green D, Gilman-Sachs A, Beamen K, Freels S, Boggio L, Allen S, Zuckerman L, Williamson, Schlegel R. Antiphospholipid antibodies, proteins C and S, and clotting activity in sickle cell disease. Journal of Laboratory and Clinical Medicine. 134:352-62, 1999.

  56. Burt RK, Kuzel TM, Fishman M, et al. Stem cell component therapy: supplementation of unmanipulated marrow with CD34 enriched peripheral blood stem cells. Bone Marrow Transplant, 23:, 381-386, 1999.

  57. Chapman GB, Elstein AS, Kuzel TM, Nadler RB, Sharifi R, Bennett CL. A multi-attribute model of prostate cancer patients’ preference for health states. Quality of Life Research, 1999 (in press).

  58. Dolan ME, McRae BL, Ferries-Rowe E, Belanich M, van Seventer GA, Guitart J, Pezen D, Kuzel TM, and Yarosh D. O6-alkyltransferase in cutaneous T-cell lymphoma: implications for treatment with alkylating agents. Clin Cancer Res 5:2059-2064, 1999.

  59. Guitart J, Variakojis D, Kuzel TM, Rosen ST. Cutaneous CD8+ T-cell infiltrates in advanced HIV infection resembling mycosis fungoides. J Am Acad Dermatol 41: 722-727, 1999.

  60. Kim SP, Knight SJ, Chmiel J, Cheeling C, Davis TC, Elstein AS, Falcone D, Kuzel T, et al. Prostate cancer quality of life and outcomes research among patients with low socioeconomic status: an overview of the VA cancer of the prostate study. Oncology 13:823-832, 1999.

  61. Sharp LK, Knight SJ, Nadler R, Albers M, Moran E, Kuzel TM, Sharifi R, and Bennett C. Quality of Life in low-income patients with metastatic prostate cancer: divergent and convergent validity of three instruments. Quality of Life Research 8:461-470, 1999.

  62. Stadler WM, Kuzel TM, Shapiro C, et al. A multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal cell carcinoma. J Clin Oncol 17:2541-2545, 1999.

  63. Kwaan HC, Guest Editor. The thrombophilic state in cancer patients. Seminars in Thrombosis and hemostasis, 25(2), 127-129, 1999.

  64. Kwaan HC, Bongu A. The hyperviscosity syndromes. Seminars in Thrombosis and Hemostasis, 25(2), 199-208, 1999.

  65. Kwaan HC, Sakurai S. Endothelial cell hyperplasia contributes to thrombosis in heparin induce thrombocytopenia. Seminars in Thrombosis and Hemostasis, 25 (suppl.1), 23-28, 1999.

  66. Hong JJ, Kwaan, HC. Hereditary defects in fibrinolysis associated with thrombosis. Seminars in Thrombosis and Hemostasis, 25 (3), 321-331, 1999.

  67. Muir JC, Krammer LM, Cameron JR, von Gunten CF. Symptom control in hospice—state of the art. The Hospice Journal 14(3/4):33-61, 1999.

  68. Muir JC, Krammer LM, von Gunten CF. Training physicians palliative care. Generations: Journal of the American Society on Aging, 23(1):91-95, 1999.

  69. Krammer L, Muir JC, Kellar-Gooding N, Williams MB, von Gunten CF. Palliative care and oncology: opportunities for oncology nursing. Oncology Nursing Updates 6(3):1-12, 1999.

  70. Mulcahy MF and Benson III AB. The role of carcinoembryonic antigen monitoring in the management of colorectal cancer. Current Oncology Reports 1: 168-172, 1999.

  71. O’Regan RM, Jordan VC, Gradishar WJ, Tamoxifen and contralateral breast cancer. J Am Col Surg, 188:678-683, 1999.

  72. Paice JA, DuPen A, Schwertz D. Catheter cleansing techniques may allow the entry of povidone-iodine into the epidural space. Oncol Nurs Forum 26:603-605, 1999.

  73. Knoerl DV, Faut-Callahan F, Paice J, Shott S. Preoperative PCA teaching program to manage postoperative pain. MEDSURG Nurs 8:25-36, 1999.

  74. Pasche B, Kolachana P, Nafa K, Satagopan J, Chen YG, Lo RS, Brener D, Yang D, Kirstein L, Oddoux C, Ostrer H, Vineis P, Varesco L, Jhanwar S, Luzzatto L, Massagué J, Ofit K. TßR-I(6A) is a candidate tumor susceptibility allele. Cancer Research 59:5678-5682, 1999.

  75. Burt RK, Constantinos G, Schroeder J, Traynor A, Stefka J, Scheuning F, Graziano F, Mineishi S, Brush M, Fishman M, Welles C, Rosen ST, Pope R. Autologous hematopoietic stem cell transplantation in refractory rheumatoid arthritis: sustained response in two of four patients. Arthritis & Rheumatism, 42(11):2281-2285, 1999.

  76. Burt RK, Guitart JK, Traynor A, Link C, Rosen ST, Pandolfino T, Kuzel TM. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of graft-versus-tumor effect. Bone Marrow Transpl.24(0)0, 1999.

  77. Chauhuan D, Hideshima T, Pandey P, Treon S, Teoh G, Raje N, Rosen ST, Krett N, Husson H, Avraham S, Kharbanda S, Anderson K. RAFTK/PYK2-dependent and independent apoptosis in multiple myeloma cells, Oncogene, 18:6733-6740, 1999.

  78. Gohongi T, Fukumura D, Boucher Y, Soff GA, Todoroki T, Jain RK. Suppression of angiogenesis at a second site by an orthotopic gallbladder tumor: Role of TGF-1. Nature Medicine 5:1203-1208, 1999.

  79. Tallman MS, Hakimian D, Kopecky KJ, Wheaton S, Wollins E, Foucar K, Cassileth PA, Habermann T, Grever M, Rowe JM, Peterson LC. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2'-deoxycoformycin and prediction of relapse. Clinical Cancer Research; 5:1665-1670, 1999.

  80. Tallman MS, Lee S, Sikic B, Paietta E, Bennett JM, Rowe JM, Wiernik PH. Mitoxantrone, etoposide and cytosine arabinoside plus cyclosporine in patients with relapsed or refractory acute myeloid leukemia: An Eastern Cooperative Oncology Group Pilot Study. Cancer; 85:358-367, 1999.

  81. Advani R, Saba HI, Tallman MS, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Sikic BI Greenberg PL. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator valspodar (PSC 833); 93:787-795. Blood, 1999.

  82. Kleinman MB, Wiley EL, Guo M, Rademaker AW, Villa M, Tallman MS, Newman SB, Gordon LI, Winter JN. Immunohistochemical detection of breast cancer cells in paired peripheral blood progenitor cell specimens collected after cytokine or cytokine and myelosuppressive chemotherapy. Bone Marrow Transplantation 23:1297-1301, 1999.

  83. Siegel RS, Tallman MS, Hakimian D, Spies W, Wollins E, Peterson LC, Meyer J. Technetium-99m sulfur colloid scanning and correlative magnetic resonance imaging in patients with hairy cell leukemia and hypocellular bone marrow biopsies after 2-chlorodeoxyadenosine (2-CdA). Leukemia Lymphoma; 35:171-177, 1999.

  84. Lothian ST, Fotis MA, von Gunten CF, Lyons J, Von Roenn J, Weitzman SA. Management case study: cancer pain management through a pharmacist-based analgesic dosing service. Am J Health-Syst Pharm 56:1119-1125, 1999.

  85. Rabkin CS, Testa MA, Huang J, Von Roenn J. Kaposi’s sarcoma and non-Hodgkin’s lymphoma incidence trends in AIDS clinical trials group study participants. J of AIDS 21:S31-S34, 1999.

  86. Anderson LM, Swaminathan S, Zackon I, Tajuddin AK, Thimmapaya B, Weitzman SA. Adenovirus-mediated tissue-targeted expression of the HSV-TKgene for the treatment of breast cancer. Gene Therapy, 6:854-864, 1999.

  87. Cerda SR, Chu SS, Garcia P, Chung J, Grumet JD, Thimmapaya B, Weitzman SA. Regulation of expression of N-methylpurine DNA glycosylase in human mammary epithelial cells: role of transcription factor AP-2. Chem. Res. Toxicol, 12:1098-1109, 1999.

  88. Gonzales M, Haan K, Baker SE, Fitchman M, Todorov I, Weitzman SA, Jones JCR. A cell signal pathway involving laminin-5, alpha-3/beta-1 integrin and MAP kinase can regulate epithelial cell proliferation. Mol. Biol. Cell, 10:259-270,1999.

  89. Jayaraman G, Srinivas R, Duggan C, Ferreira E, Swaminathan S, Somasundaram K, Williams J, Hauser C, Kurkinen M, Dhar R, Weitzman S, Buttice G, Thimmapaya B. p300/cAMP-responsive element binding protein interactions with Ets-1 and Ets-2 in the transcriptional activation of the human stromelysin promoter. J. Biol. Chem, 274:17342-17352, 1999.

  90. Tamatani T. Turk P, Weitzman S, Oyasu R. Tumorigenic conversion of a rat urothelial cell line by human polymorphonuclear leukocytes activated by lipopolysaccharide. Japan J. Cancer Res., 90:829-836, 1999.

  91. Guo MH, Miller WM, Papoutsakis ET, Patel S, James C, Goolsby C, Winter JN. Ex vivo expansion of CFU-GM and BFU-E in unselected PBMC cultures with Flt3L is enhanced by autologous plasma. Cytotherapy 1:183-194, 1999.

  92. Lefebvre P, Winter JN, Kahn L, Giri JG, Cohen I. Megakaryocyte ex vivo expansion potential of three hematopoietic sources in serum and serum-free medium. J Hematotherapy; 8: 199-208, 1999.